P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4... by S. Johnston, M. Toi, J. O’Shaughnessy, P. Rastogi, M. Campone, P. Neven, C.S. Huang, J. Huober, G. Garnica Jaliffe, I. Cicin, S. Tolaney, M.P. Goetz, H. Rugo, E. Senkus, L. Testa, L. Del Mastro, C. Shimizu, R. Wei, A. Shahir, M. Munoz, B. San Antonio, V. Andre, N. Harbeck, M. Martín

Get full text